Loading…

Use of high-dose ciprofloxacin for recurrent biofilm-forming multidrug-resistant Klebsiella pneumoniae bacteremia

is a significant nosocomial pathogen. We aimed to assess the clinical success following high-dose ciprofloxacin for recurrent bacteremia from biofilm-forming multidrug resistant in a liver transplanted patient. A 55-year-old male had undergone liver transplantation and at day 10 he developed fever a...

Full description

Saved in:
Bibliographic Details
Published in:Germs (Bucureşti) 2021-09, Vol.11 (3), p.449-453
Main Authors: Jayaweera, Jayaweera Arachchige Asela Sampath, Kothalawala, Mahen
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 453
container_issue 3
container_start_page 449
container_title Germs (Bucureşti)
container_volume 11
creator Jayaweera, Jayaweera Arachchige Asela Sampath
Kothalawala, Mahen
description is a significant nosocomial pathogen. We aimed to assess the clinical success following high-dose ciprofloxacin for recurrent bacteremia from biofilm-forming multidrug resistant in a liver transplanted patient. A 55-year-old male had undergone liver transplantation and at day 10 he developed fever and dysuria. Two blood cultures became positive and were identified by Vitek2 (BioMérieux, USA) as From his urine was isolated. Based on antimicrobial susceptibility (AST) panel (Vitek2), i.v. meropenem 1 g 8 hourly and i.v. amikacin 15 mg/kg/ daily (5 days) were started (the isolate was ciprofloxacin-resistant). Following 14 days of meropenem he was discharged and 3 days later he was readmitted with fever and dysuria. Since the blood and urine isolate was , based on AST 21 days of meropenem were given, the patient was discharged and 3 days later he was readmitted with fever and dysuria. Since this was the 3 episode with bacteremia, to exclude the focus of infection contrast-enhanced computed tomography and F-fluorodeoxyglucose-positron emission tomography were done but both were normal.Based on multilocus sequence typing (MLST) and microtiter plate assay, biofilm forming -positive (+) CC23 was found. The patient was having continuous asymptomatic bacteriuria with similar ( -positive (+) CC23) isolate; we opted for high dose oral ciprofloxacin (800 mg, 8 hourly) for 7 days. Following a high dose of oral ciprofloxacin, we were able to achieve urinary microbial clearance and a permanent cure following ( -positive (+) CC23) bacteremia. This could be a promising therapy to achieve microbial clearance from biofilm-forming multidrug-resistant .
doi_str_mv 10.18683/germs.2021.1282
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8548043</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>34722367</sourcerecordid><originalsourceid>FETCH-LOGICAL-p148t-12c5db0d3821a3d85b80916da65178181323b874504e29439ad851b466d117423</originalsourceid><addsrcrecordid>eNpVkMtKxDAUhoMozjDO3pXkBTrm1iTdCDJ4wwE3zrokTdqJJE1NWtG3t-AFPZtz-_-PwwHgHKMNllzSy86mkDcEEbzBRJIjsCSEyYJUlTj-Uy_AOucXNIdEiAt-ChaUCUIoF0vwus8WxhYeXHcoTJybxg0ptj6-q8b1sI0JJttMKdl-hNrF1vlQzNPg-g6GyY_OpKkrks0uj2rWPHqrs7PeKzj0dgqxd8pCrZrRJhucOgMnrfLZrr_zCuxvb56398Xu6e5he70rBszkWGDSlEYjQyXBihpZaokqzI3iJRYSS0wJ1VKwEjFLKkYrNWuwZpwbjAUjdAWuvrjDpIM1zXx_Ur4ekgsqfdRRufr_pneHuotvtSyZRIzOgIu_gF_nz_PoJxcuddI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Use of high-dose ciprofloxacin for recurrent biofilm-forming multidrug-resistant Klebsiella pneumoniae bacteremia</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central</source><creator>Jayaweera, Jayaweera Arachchige Asela Sampath ; Kothalawala, Mahen</creator><creatorcontrib>Jayaweera, Jayaweera Arachchige Asela Sampath ; Kothalawala, Mahen</creatorcontrib><description>is a significant nosocomial pathogen. We aimed to assess the clinical success following high-dose ciprofloxacin for recurrent bacteremia from biofilm-forming multidrug resistant in a liver transplanted patient. A 55-year-old male had undergone liver transplantation and at day 10 he developed fever and dysuria. Two blood cultures became positive and were identified by Vitek2 (BioMérieux, USA) as From his urine was isolated. Based on antimicrobial susceptibility (AST) panel (Vitek2), i.v. meropenem 1 g 8 hourly and i.v. amikacin 15 mg/kg/ daily (5 days) were started (the isolate was ciprofloxacin-resistant). Following 14 days of meropenem he was discharged and 3 days later he was readmitted with fever and dysuria. Since the blood and urine isolate was , based on AST 21 days of meropenem were given, the patient was discharged and 3 days later he was readmitted with fever and dysuria. Since this was the 3 episode with bacteremia, to exclude the focus of infection contrast-enhanced computed tomography and F-fluorodeoxyglucose-positron emission tomography were done but both were normal.Based on multilocus sequence typing (MLST) and microtiter plate assay, biofilm forming -positive (+) CC23 was found. The patient was having continuous asymptomatic bacteriuria with similar ( -positive (+) CC23) isolate; we opted for high dose oral ciprofloxacin (800 mg, 8 hourly) for 7 days. Following a high dose of oral ciprofloxacin, we were able to achieve urinary microbial clearance and a permanent cure following ( -positive (+) CC23) bacteremia. This could be a promising therapy to achieve microbial clearance from biofilm-forming multidrug-resistant .</description><identifier>ISSN: 2248-2997</identifier><identifier>EISSN: 2248-2997</identifier><identifier>DOI: 10.18683/germs.2021.1282</identifier><identifier>PMID: 34722367</identifier><language>eng</language><publisher>Romania: Asociația pentru Creşterea Vizibilității Cercetării Ştiințifice (ACVCS)</publisher><subject>Case Report</subject><ispartof>Germs (Bucureşti), 2021-09, Vol.11 (3), p.449-453</ispartof><rights>GERMS.</rights><rights>GERMS 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548043/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548043/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34722367$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jayaweera, Jayaweera Arachchige Asela Sampath</creatorcontrib><creatorcontrib>Kothalawala, Mahen</creatorcontrib><title>Use of high-dose ciprofloxacin for recurrent biofilm-forming multidrug-resistant Klebsiella pneumoniae bacteremia</title><title>Germs (Bucureşti)</title><addtitle>Germs</addtitle><description>is a significant nosocomial pathogen. We aimed to assess the clinical success following high-dose ciprofloxacin for recurrent bacteremia from biofilm-forming multidrug resistant in a liver transplanted patient. A 55-year-old male had undergone liver transplantation and at day 10 he developed fever and dysuria. Two blood cultures became positive and were identified by Vitek2 (BioMérieux, USA) as From his urine was isolated. Based on antimicrobial susceptibility (AST) panel (Vitek2), i.v. meropenem 1 g 8 hourly and i.v. amikacin 15 mg/kg/ daily (5 days) were started (the isolate was ciprofloxacin-resistant). Following 14 days of meropenem he was discharged and 3 days later he was readmitted with fever and dysuria. Since the blood and urine isolate was , based on AST 21 days of meropenem were given, the patient was discharged and 3 days later he was readmitted with fever and dysuria. Since this was the 3 episode with bacteremia, to exclude the focus of infection contrast-enhanced computed tomography and F-fluorodeoxyglucose-positron emission tomography were done but both were normal.Based on multilocus sequence typing (MLST) and microtiter plate assay, biofilm forming -positive (+) CC23 was found. The patient was having continuous asymptomatic bacteriuria with similar ( -positive (+) CC23) isolate; we opted for high dose oral ciprofloxacin (800 mg, 8 hourly) for 7 days. Following a high dose of oral ciprofloxacin, we were able to achieve urinary microbial clearance and a permanent cure following ( -positive (+) CC23) bacteremia. This could be a promising therapy to achieve microbial clearance from biofilm-forming multidrug-resistant .</description><subject>Case Report</subject><issn>2248-2997</issn><issn>2248-2997</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpVkMtKxDAUhoMozjDO3pXkBTrm1iTdCDJ4wwE3zrokTdqJJE1NWtG3t-AFPZtz-_-PwwHgHKMNllzSy86mkDcEEbzBRJIjsCSEyYJUlTj-Uy_AOucXNIdEiAt-ChaUCUIoF0vwus8WxhYeXHcoTJybxg0ptj6-q8b1sI0JJttMKdl-hNrF1vlQzNPg-g6GyY_OpKkrks0uj2rWPHqrs7PeKzj0dgqxd8pCrZrRJhucOgMnrfLZrr_zCuxvb56398Xu6e5he70rBszkWGDSlEYjQyXBihpZaokqzI3iJRYSS0wJ1VKwEjFLKkYrNWuwZpwbjAUjdAWuvrjDpIM1zXx_Ur4ekgsqfdRRufr_pneHuotvtSyZRIzOgIu_gF_nz_PoJxcuddI</recordid><startdate>20210929</startdate><enddate>20210929</enddate><creator>Jayaweera, Jayaweera Arachchige Asela Sampath</creator><creator>Kothalawala, Mahen</creator><general>Asociația pentru Creşterea Vizibilității Cercetării Ştiințifice (ACVCS)</general><scope>NPM</scope><scope>5PM</scope></search><sort><creationdate>20210929</creationdate><title>Use of high-dose ciprofloxacin for recurrent biofilm-forming multidrug-resistant Klebsiella pneumoniae bacteremia</title><author>Jayaweera, Jayaweera Arachchige Asela Sampath ; Kothalawala, Mahen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p148t-12c5db0d3821a3d85b80916da65178181323b874504e29439ad851b466d117423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Case Report</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jayaweera, Jayaweera Arachchige Asela Sampath</creatorcontrib><creatorcontrib>Kothalawala, Mahen</creatorcontrib><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Germs (Bucureşti)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jayaweera, Jayaweera Arachchige Asela Sampath</au><au>Kothalawala, Mahen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of high-dose ciprofloxacin for recurrent biofilm-forming multidrug-resistant Klebsiella pneumoniae bacteremia</atitle><jtitle>Germs (Bucureşti)</jtitle><addtitle>Germs</addtitle><date>2021-09-29</date><risdate>2021</risdate><volume>11</volume><issue>3</issue><spage>449</spage><epage>453</epage><pages>449-453</pages><issn>2248-2997</issn><eissn>2248-2997</eissn><abstract>is a significant nosocomial pathogen. We aimed to assess the clinical success following high-dose ciprofloxacin for recurrent bacteremia from biofilm-forming multidrug resistant in a liver transplanted patient. A 55-year-old male had undergone liver transplantation and at day 10 he developed fever and dysuria. Two blood cultures became positive and were identified by Vitek2 (BioMérieux, USA) as From his urine was isolated. Based on antimicrobial susceptibility (AST) panel (Vitek2), i.v. meropenem 1 g 8 hourly and i.v. amikacin 15 mg/kg/ daily (5 days) were started (the isolate was ciprofloxacin-resistant). Following 14 days of meropenem he was discharged and 3 days later he was readmitted with fever and dysuria. Since the blood and urine isolate was , based on AST 21 days of meropenem were given, the patient was discharged and 3 days later he was readmitted with fever and dysuria. Since this was the 3 episode with bacteremia, to exclude the focus of infection contrast-enhanced computed tomography and F-fluorodeoxyglucose-positron emission tomography were done but both were normal.Based on multilocus sequence typing (MLST) and microtiter plate assay, biofilm forming -positive (+) CC23 was found. The patient was having continuous asymptomatic bacteriuria with similar ( -positive (+) CC23) isolate; we opted for high dose oral ciprofloxacin (800 mg, 8 hourly) for 7 days. Following a high dose of oral ciprofloxacin, we were able to achieve urinary microbial clearance and a permanent cure following ( -positive (+) CC23) bacteremia. This could be a promising therapy to achieve microbial clearance from biofilm-forming multidrug-resistant .</abstract><cop>Romania</cop><pub>Asociația pentru Creşterea Vizibilității Cercetării Ştiințifice (ACVCS)</pub><pmid>34722367</pmid><doi>10.18683/germs.2021.1282</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2248-2997
ispartof Germs (Bucureşti), 2021-09, Vol.11 (3), p.449-453
issn 2248-2997
2248-2997
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8548043
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central
subjects Case Report
title Use of high-dose ciprofloxacin for recurrent biofilm-forming multidrug-resistant Klebsiella pneumoniae bacteremia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T12%3A24%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20high-dose%20ciprofloxacin%20for%20recurrent%20biofilm-forming%20multidrug-resistant%20Klebsiella%20pneumoniae%20bacteremia&rft.jtitle=Germs%20(Bucure%C5%9Fti)&rft.au=Jayaweera,%20Jayaweera%20Arachchige%20Asela%20Sampath&rft.date=2021-09-29&rft.volume=11&rft.issue=3&rft.spage=449&rft.epage=453&rft.pages=449-453&rft.issn=2248-2997&rft.eissn=2248-2997&rft_id=info:doi/10.18683/germs.2021.1282&rft_dat=%3Cpubmed%3E34722367%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p148t-12c5db0d3821a3d85b80916da65178181323b874504e29439ad851b466d117423%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/34722367&rfr_iscdi=true